LabMedica

Download Mobile App
Recent News Expo
WHX Labs Dubai 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LINGO-1 May Lead to MS Therapy

By Biotechdaily staff writers
Posted on 15 Jun 2005
Scientists have identified a molecule in the central nervous system (CNS) called LINGO-1 that plays a role in nerve repair and may lead to pathways for treating multiple sclerosis (MS) and other demyelinating diseases.

Research findings indicate that LINGO-1 is a molecular switch that controls the ability of CNS cells to myelinate. Scientists discovered that LINGO-1 normally acts to prevent myelination and its normal function could be blocked in laboratory tissue culture. They were able to generate large quantities of myelin by blocking LINGO-1 and, for the first time ever in a laboratory, were able to wrap it correctly around nerves.

"We believe that the LINGO-1 research has significantly added to the body of knowledge about nerve repair in multiple sclerosis and other demyelinating diseases,” observed John Richert, M.D., vice president, clinical and research programs, National Multiple Sclerosis Society. "We hope it will one day lead to improved treatments for MS and the repair of the central nervous system.”

MS is a chronic disease of the CNS in which the body's own immune cells break down myelin, a fatty substance that surrounds nerve cells like the insulation around a wire. Without myelin, nerves lose the ability to conduct impulses and eventually die. In MS patients, the CNS cells that wrap nerves in myelin fail to restore the missing myelin sheath following an immune system attack.

LINGO-1 was discovered by scientists at Biogen Idec (Cambridge, MA, USA). "Although it is still uncertain whether we can transform these observations into a therapy, our research team has provided the first indications of a new pathway that may enable us to repair the nerve damage found in patients afflicted by MS and other serious demyelinating diseases,” noted Michael Gilman, Ph.D., executive vice president, research, Biogen Idec. The findings were reported in the June 2005 issue of Nature Neuroscience.




Related Links:
Biogen

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Sample Transportation System
Tempus1800 Necto

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
15 Jun 2005  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
15 Jun 2005  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
15 Jun 2005  |   BioResearch